Figure count: Four
What is already known about this subject:
High-dose methotrexate is commonly used in acute lymphoblastic leukemia.
The target 24-hours methotrexate concentrations were set at 33 μmol/L
for 3 g/m2 dose group and 65 μmol/L for 5
g/m2 dose group.
The relationship between target 24-hours methotrexate concentration and
methotrexate excretion delay with survival have not been fully
confirmed.
What this study adds:
Achieving the target 24-hours methotrexate concentration during
high-dose methotrexate therapy is not the useful indicator to predict
the survival of acute lymphoblastic leukemia patients.
Patients with more than 20% of methotrexate excretion delay courses had
significant worse prognosis.
More serious consideration should be taking into account on the
leucovorin rescue.